Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study

Background Many patients with psoriatic arthritis do not reach minimal disease activity (MDA) on methotrexate alone. This phase 4 open-label study aimed to compare attainment of MDA following introduction of adalimumab with methotrexate escalation in patients with psoriatic arthritis who do not reac...

Full description

Bibliographic Details
Main Authors: Coates, LC, Tillett, W, D’Agostino, MA, Rahman, P, Behrens, F, McDearmon-Blondell, EL, Bu, X, Chen, L, Kapoor, M, Conaghan, PG, Mease, P
Format: Journal article
Language:English
Published: Elsevier 2022